Nonalcoholic Steatohepatitis (NASH) - Market Insights, Epidemiology and Market Forecast - 2027

  • ID: 4330675
  • Drug Pipelines
  • Region: Global
  • 120 Pages
  • DelveInsight
1 of 4
Total Seven Major Market Size is Expected to Have USD 49 Billion by 2027
Nonalcoholic Steatohepatitis (NASH) - Market Insights, Epidemiology and Market Forecast-2027 provides a disease overview of the Nonalcoholic Steatohepatitis (NASH) along with the epidemiology and the market scenario in the 7MM - United States, EU5 (Germany, France, Spain Italy, United Kingdom) and Japan.

The report covers the therapeutics market revenue, treatment practice and Nonalcoholic Steatohepatitis (NASH) forecasted market share from 2017 to 2027 segmented by seven major markets. In addition, the report also includes global forecast of epidemiology of Nonalcoholic Steatohepatitis (NASH) till 2027. Our epidemiology forecast covers the prevalent population as well as the diagnosed population having Nonalcoholic Steatohepatitis (NASH).

The report also covers the detailed market size forecast for 7MM. According to research, it is estimated that the market size of Nonalcoholic Steatohepatitis (NASH) in 7MM shall increase and reach up to 49.25 Billion in 2027, with the compound annual growth rate (CAGR) of 23.0% for the period i.e., 2015-2027.

Nonalcoholic Steatohepatitis (NASH) is a subtype of NAFLD (Nonalcoholic Fatty Liver Disease) that is characterized by accumulation of large amount of fat in the liver, along with inflammation and scarring. NASH is one of the most common liver related health problem and is considered to be strongly associated with insulin resistance, central obesity, reduced glucose tolerance, type 2 diabetes mellitus (T2DM), arterial hypertension, and hypertriglyceridemia. The condition can further progress to cirrhosis, liver failure and rarely liver cancer.

Key Coverage and Benefits:
  • The report will help in developing business strategies by understanding the trends shaping and driving the global Nonalcoholic Steatohepatitis (NASH) market.
  • Organize sales and marketing efforts by identifying the best opportunities for Nonalcoholic Steatohepatitis (NASH) in US, European Union 5 (EU5 - Germany, Spain, Italy, France and United Kingdom) and Japan.
  • To understand the future market competition in the global Nonalcoholic Steatohepatitis (NASH) market and Insightful review of the key market drivers and barriers.
  • To understand the regulatory scenario in major markets.
Note: Please allow up to 24 hours for delivery after payment has been made.
READ MORE
Note: Product cover images may vary from those shown
2 of 4
1. Report Introduction

2. Non-Alcoholic Steatohepatitis Market Overview at a Glance

3. Total Market Share Distribution of Non-Alcoholic Steatohepatitis for 7 MM in 2016

4. Total Market Share Distribution of Non-Alcoholic Steatohepatitis for 7 MM in 2027

5. Non-Alcoholic Steatohepatitis
5.1. Introduction
5.2. Types
5.3. Classification of NASH: Stages of Fibrosis
5.4. Causes
5.5. Pathophysiology
5.6. Symptoms
5.7. Diagnosis

6. Epidemiology and Patient Population

7. Key Points:

8. Population and Forecast Parameters

9. Prevalent Population of NASH in 7MM

10. Region-Wise Prevalent Population of NASH

11. Diagnosed Population of NASH in 7MM

12. Region-Wise Diagnosed Population of NASH
12.1. United States
12.1.1. Prevalent Population of NASH
12.1.2. Diagnosed Population of NASH
12.2. Germany
12.2.1. Prevalent Population of NASH
12.2.2. Diagnosed Population of NASH
12.3. France
12.3.1. Prevalent Population of NASH
12.3.2. Diagnosed Population of NASH
12.4. Italy
12.4.1. Prevalent Population of NASH
12.4.2. Diagnosed Population of NASH
12.5. Spain
12.5.1. Prevalent Population of NASH
12.5.2. Diagnosed Population of NASH
12.6. United Kingdom
12.6.1. Prevalent Population of NASH
12.6.2. Diagnosed Population of NASH
12.7. Japan
12.7.1. Prevalent Population of NASH
12.7.2. Diagnosed Population of NASH

13. Treatment Algorithm

14. American Association for the Study of Liver Diseases (AASLD) Current Recommendations for NAFLD/NASH

15. EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease

16. Guideline for NAFLD/NASH, by the Japanese Society of Gastroenterology (JSG) in cooperation with “The Japan Society of Hepatology”

17. Unmet Needs

18. Emerging Drugs
18.1. Phase-III Drugs Analysis
18.2. Phase-II Drugs Analysis

19. Emerging Therapies
19.1. Elafibranor(GFT505): GenfitPharma
19.1.1. Regulatory Milestones
19.1.2. Other development activities
19.1.3. Clinical Development
19.1.4. Ongoing Trials Information
19.1.5. Safety and Efficacy
19.1.6. Advantages and Disadvantages
19.1.7. Product Profile
19.2. Obeticholic Acid (OCA): Intercept Pharmaceuticals, Inc.
19.2.1. Regulatory milestones
19.2.2. Other development activities
19.2.3. Clinical Development
19.2.4. Ongoing Trials Information
19.2.5. Safety and Efficacy
19.2.6. Advantages and Disadvantages
19.2.7. Product Profile
19.3. Selonsertib (Ask-1 Inhibitor): Gilead Sciences, Inc.
19.3.1. Other development activities
19.3.2. Clinical Development
19.3.3. Clinical Pipeline Activity
19.3.4. Safety and Efficacy
19.3.5. Advantages and Disadvantages
19.3.6. Product Profile
19.4. Cenicriviroc (CVC): Allergan/Tobira Therapeutics
19.4.1. Regulatory milestones
19.4.2. Other development activities
19.4.3. Clinical Development
19.4.4. Ongoing Trials Information
19.4.5. Safety and Efficacy
19.4.6. Advantages and Disadvantages
19.4.7. Product Profile
19.5. NGM282: NGM Biopharmacueticals, Inc.
19.5.1. Other development activities
19.5.2. Clinical Development
19.5.3. Ongoing Trials Information
19.5.4. Safety and Efficacy
19.5.5. Advantages and Disadvantages
19.5.6. Product Profile
19.6. BMS-986036: Bristol-Myers Squibb Company
19.6.1. Other development activities
19.6.2. Clinical Development
19.6.3. Ongoing trials information
19.6.4. Safety and Efficacy
19.6.5. Advantages and Disadvantages
19.6.6. Product Profile
19.7. Emricasan: Conatus Pharmaceuticals Inc.
19.7.1. Regulatory milestones
19.7.2. Other development activities
19.7.3. Clinical Development
19.7.4. Ongoing trials information
19.7.5. Safety and Efficacy
19.7.6. Product Profile
19.8. IVA337: Inventiva Pharma
19.8.1. Regulatory milestones
19.8.2. Clinical Development
19.8.3. Ongoing trial information
19.8.4. Safety and Efficacy
19.8.5. Product Profile

20. Nonalcoholic Steatohepatitis (NASH): Country-Wise Market Analysis
20.1. Total Market Size of Nonalcoholic Steatohepatitis (NASH) for 7 MM in 2015-2027

21. United States
21.1. Market Size of NASH in United States

22. Europe

23. Germany
23.1. Market Size of NASH in Germany

24. France
24.1. Market Size of NASH in France

25. Italy
25.1. Market Size of NASH in Italy

26. Spain
26.1. Market Size of NASH in Spain

27. United Kingdom
27.1. Market Size of NASH in United Kingdom

28. Japan
28.1. Market Size of NASH in Japan

29. Market Drivers

30. Market Barriers

31. Appendix

32. Report Methodology

33. Consulting Services

34. Disclaimer

35. About

List of Tables
Table 1: Total Prevalent Population of NASH in 7 MM (2015-2027)
Table 2: Region-Wise Prevalent Population of NASH (2015-2027)
Table 3: Total Diagnosed Population of NASH in 7 MM (2015-2027)
Table 4: Region-Wise Diagnosed Population of NASH (2015-2027)
Table 5: Prevalent Population of NASH based on Fibrosis Score in United States (2015-2027)
Table 6: Diagnosed Population of NASH in United States (2015-2027)
Table 7: Prevalent Population of NASH based on Fibrosis Score in Germany (2015-2027)
Table 8: Diagnosed Population of NASH in Germany (2015-2027)
Table 9: Prevalent Population of NASH based on Fibrosis Score in France (2015-2027)
Table 10: Diagnosed Population of NASH in France (2015-2027)
Table 11: Prevalent Population of NASH based on Fibrosis Score in Italy (2015-2027)
Table 12: Diagnosed Population of NASH in Italy (2015-2027)
Table 13: Prevalent Population of NASH based on Fibrosis Score in Spain (2015-2027)
Table 14: Diagnosed Population of NASH in Spain (2015-2027)
Table 15: Prevalent Population of NASH based on Fibrosis Score in United Kingdom (2015-2027)
Table 16: Diagnosed Population of NASH in United Kingdom (2015-2027)
Table 17: Prevalent Population of NASH based on Fibrosis Score in Japan (2015-2027)
Table 18: Diagnosed Population of NASH in Japan (2015-2027)
Table 19: Treatment Algorithm of Nonalcoholic Steatohepatitis (NASH)
Table 20: Medications for Nonalcoholic Steatohepatitis (NASH)
Table 21: Management of NAFLD based on histology
Table 22: AASLD Current Recommendations for NAFLD/NASH
Table 23: EASL-EASD-EASO Clinical Practice Guidelines for the management of NAFLD
Table 24: Guideline for NAFLD/NASH, by the Japanese Society of Gastroenterology (JSG)
Table 25: Market Size of Nonalcoholic Steatohepatitis (NASH) in 7MM (USD Billion) (2015-2027)
Table 26: United States Market Size of Nonalcoholic Steatohepatitis (NASH) in USD, Billion (2015-2027)
Table 27: Germany Market Size of Nonalcoholic Steatohepatitis (NASH) in USD, Billion (2015-2027)
Table 28: France Market Size of Nonalcoholic Steatohepatitis (NASH) in USD, Billion (2015-2027)
Table 29: Italy Market Size of Nonalcoholic Steatohepatitis (NASH) in USD, Billion (2015-2027)
Table 30: Spain Market Size of Nonalcoholic Steatohepatitis (NASH) in USD, Billion (2015-2027)
Table 31: United Kingdom Market Size of Nonalcoholic Steatohepatitis (NASH) in USD, Billion (2015-2027)
Table 32: Japan Market Size of Nonalcoholic Steatohepatitis (NASH) in USD, Billion (2015-2027)

List of Figures
Figure 1: Types of NASH
Figure 2: Stages of NASH
Figure 3: Classification of NASH
Figure 4: Pathophysiology of NASH
Figure 5: Pathophysiology of NASH: Lipolysis of adipose tissue
Figure 6: Pathophysiology of NASH: Dietary factors
Figure 7: Pathophysiology of NASH: Kupffer cells
Figure 8: Total Prevalent Population of NASH in 7 MM (2015-2027)
Figure 9: Region-Wise Prevalent Population of NASH (2015-2027)
Figure 10: Total Diagnosed Population of NASH in 7 MM (2015-2027)
Figure 11: Region-Wise Diagnosed Population of NASH (2015-2027)
Figure 12: Prevalent Population of NASH based on Fibrosis Score in United States (2015-2027)
Figure 13: Diagnosed Population of NASH in United States (2015-2027)
Figure 14: Prevalent Population of NASH based on Fibrosis Score in Germany (2015-2027)
Figure 15: Diagnosed Population of NASH in Germany (2015-2027)
Figure 16: Prevalent Population of NASH based on Fibrosis Score in France (2015-2027)
Figure 17: Diagnosed Population of NASH in France (2015-2027)
Figure 18: Prevalent Population of NASH based on Fibrosis Score in Italy (2015-2027)
Figure 19: Diagnosed Population of NASH in Italy (2015-2027)
Figure 20: Prevalent Population of NASH based on Fibrosis Score in Spain (2015-2027)
Figure 21: Diagnosed Population of NASH in Spain (2015-2027)
Figure 22: Prevalent Population of NASH based on Fibrosis Score in United Kingdom (2015-2027)
Figure 23: Diagnosed Population of NASH in United Kingdom (2015-2027)
Figure 24: Prevalent Population of NASH based on Fibrosis Score in Japan (2015-2027)
Figure 25: Diagnosed Population of NASH in Japan (2015-2027)
Figure 26: Unmet needs: NASH
Figure 27: United States Market Size of Nonalcoholic Steatohepatitis (NASH) in USD, Billion (2015-2027)
Figure 28: Germany Market Size of Nonalcoholic Steatohepatitis (NASH) in USD, Billion (2015-2027)
Figure 29: France Market Size of Nonalcoholic Steatohepatitis (NASH) in USD, Million (2015-2027)
Figure 30: Italy Market Size of Nonalcoholic Steatohepatitis (NASH) in USD, Billion (2015-2027)
Figure 31: Spain Market Size of Nonalcoholic Steatohepatitis (NASH) in USD, Billion (2015-2027)
Figure 32: United Kingdom Market Size of Nonalcoholic Steatohepatitis (NASH) in USD, Million (2015-2027)
Figure 33: Japan Market Size of Nonalcoholic Steatohepatitis (NASH) in USD, Million (2015-2027)
Figure 34: Market Drivers: NASH
Figure 35: Market Barriers: NASH
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
Note: Product cover images may vary from those shown
Adroll
adroll